Synapse - Neil Segal

Results (213)

Translational considerations on the outlook of immunotherapy for colorectal cancer

Journal Article

Segal, N. H.; Saltz, L. B.
Current Colorectal Cancer Reports (2015)

Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: A retrospective analysis

Journal Article

Wesa, K. M.; Segal, N. H.; Cronin, A. M.; Sjoberg, D. D.; Jacobs, G. N.; Coleton, M. I.; Fleisher, M.; Dnistrian, A. M.; Saltz, L. B.; Cassileth, B. R.
Nutrition and Cancer (2015)

Fulltext@MSK | Save

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

Meeting Abstract

Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody

Meeting Abstract

Segal, N. H.; Antonia, S. J.; Brahmer, J. R.; Maio, M.; Blake-Haskins, A.; Li, X.; Vasselli, J.; Ibrahim, R. A.; Lutzky, J.; Khieif, S.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer

Meeting Abstract

Segal, N. H.; Gopal, A. K.; Bhatia, S.; Kohrt, H. E.; Levy, R.; Pishvalan, M. J.; Houot, R.; Bartlett, N.; Nghlem, P.; Kronenberg, S. A.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors

Meeting Abstract

Segal, N. H.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T.; Wolchok, J. D.; Urba, W. J.; Fox, B. A.; Topallan, S. L.; Pardoll, D. M.; Kollia, G.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors

Meeting Abstract

Lutzky, J.; Antonia, S. J.; Blake-Haskins, A.; Li, X.; Robbins, P. B.; Shaiabl, A. M.; Vasseill, J.; Ibrahim, R. A.; Khleif, S.; Segal, N. H.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two phase I studies

Meeting Abstract

Segal, N. H.; Dotan, E.; Berlin, J. D.; Starodub, A. N.; Guarino, M. J.; Saltz, L. B.; Maliakal, P. P.; Govindan, S. V.; Wegener, W. A.; Sharkey, R. M.; more...
Cancer Research (2014)

Fulltext@MSK | Save

Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)